Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Impact and management of Campylobacter in human medicine--European perspective.

Kist M.

Int J Infect Dis. 2002 Dec;6 Suppl 3:3S44-7; discussion 3S47-8, 3S53-8.

2.

Campylobacter jejuni survives within epithelial cells by avoiding delivery to lysosomes.

Watson RO, Galán JE.

PLoS Pathog. 2008 Jan;4(1):e14. doi: 10.1371/journal.ppat.0040014.

3.

A comparison of self-reported joint symptoms following infection with different enteric pathogens: effect of HLA-B27.

Schiellerup P, Krogfelt KA, Locht H.

J Rheumatol. 2008 Mar;35(3):480-7. Epub 2008 Jan 15.

PMID:
18203313
4.

Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases.

Doorduyn Y, Van Pelt W, Siezen CL, Van Der Horst F, Van Duynhoven YT, Hoebee B, Janssen R.

Epidemiol Infect. 2008 Sep;136(9):1225-34. Epub 2007 Dec 7.

5.

Genetic polymorphisms in immunoresponse genes TNFA, IL6, IL10, and TLR4 are associated with recurrent acute otitis media.

Emonts M, Veenhoven RH, Wiertsema SP, Houwing-Duistermaat JJ, Walraven V, de Groot R, Hermans PW, Sanders EA.

Pediatrics. 2007 Oct;120(4):814-23.

PMID:
17908769
6.

Genetic polymorphisms of macrophage-mediators in Guillain-Barré syndrome.

Geleijns K, Emonts M, Laman JD, van Rijs W, van Doorn PA, Hermans PW, Jacobs BC.

J Neuroimmunol. 2007 Oct;190(1-2):127-30. Epub 2007 Aug 30.

PMID:
17761309
7.

Campylobacter jejuni: molecular biology and pathogenesis.

Young KT, Davis LM, Dirita VJ.

Nat Rev Microbiol. 2007 Sep;5(9):665-79. Review.

PMID:
17703225
8.

A major role for intestinal epithelial nucleotide oligomerization domain 1 (NOD1) in eliciting host bactericidal immune responses to Campylobacter jejuni.

Zilbauer M, Dorrell N, Elmi A, Lindley KJ, Schüller S, Jones HE, Klein NJ, Núnez G, Wren BW, Bajaj-Elliott M.

Cell Microbiol. 2007 Oct;9(10):2404-16. Epub 2007 May 23. Erratum in: Cell Microbiol. 2007 Oct;9(10):2541.

9.

Role of the small Rho GTPases Rac1 and Cdc42 in host cell invasion of Campylobacter jejuni.

Krause-Gruszczynska M, Rohde M, Hartig R, Genth H, Schmidt G, Keo T, König W, Miller WG, Konkel ME, Backert S.

Cell Microbiol. 2007 Oct;9(10):2431-44. Epub 2007 May 23.

PMID:
17521326
10.

Comparison of virulence-associated in vitro properties of typed strains of Campylobacter jejuni from different sources.

Coote JG, Stewart-Tull DE, Owen RJ, Bolton FJ, Siemer BL, Candlish D, Thompson DH, Wardlaw AC, On SL, Candlish A, Billcliffe B, Jordan PJ, Kristiansen K, Borman P.

J Med Microbiol. 2007 Jun;56(Pt 6):722-32.

PMID:
17510255
11.

Re-analysis of the risks attributed to ciprofloxacin-resistant Campylobacter jejuni infections.

Wassenaar TM, Kist M, de Jong A.

Int J Antimicrob Agents. 2007 Sep;30(3):195-201. Epub 2007 Apr 8. Review.

PMID:
17420115
12.

A community outbreak of Campylobacter jejuni infection from a chlorinated public water supply.

Richardson G, Thomas DR, Smith RM, Nehaul L, Ribeiro CD, Brown AG, Salmon RL.

Epidemiol Infect. 2007 Oct;135(7):1151-8. Epub 2007 Feb 9.

13.

Role of infection in irritable bowel syndrome.

Spiller RC.

J Gastroenterol. 2007 Jan;42 Suppl 17:41-7. Review.

PMID:
17238025
14.

A MyD88-deficient mouse model reveals a role for Nramp1 in Campylobacter jejuni infection.

Watson RO, Novik V, Hofreuter D, Lara-Tejero M, Galán JE.

Infect Immun. 2007 Apr;75(4):1994-2003. Epub 2006 Dec 28.

15.
16.

C57BL/6 and congenic interleukin-10-deficient mice can serve as models of Campylobacter jejuni colonization and enteritis.

Mansfield LS, Bell JA, Wilson DL, Murphy AJ, Elsheikha HM, Rathinam VA, Fierro BR, Linz JE, Young VB.

Infect Immun. 2007 Mar;75(3):1099-115. Epub 2006 Nov 27.

17.

Regulation of chicken contamination is urgently needed to control New Zealand's serious campylobacteriosis epidemic.

Baker M, Wilson N, Ikram R, Chambers S, Shoemack P, Cook G.

N Z Med J. 2006 Oct 13;119(1243):U2264.

PMID:
17063200
18.

Mannose-binding lectin contributes to the severity of Guillain-Barré syndrome.

Geleijns K, Roos A, Houwing-Duistermaat JJ, van Rijs W, Tio-Gillen AP, Laman JD, van Doorn PA, Jacobs BC.

J Immunol. 2006 Sep 15;177(6):4211-7.

19.

Novel surface polypeptides of Campylobacter jejuni as traveller's diarrhoea vaccine candidates discovered by proteomics.

Prokhorova TA, Nielsen PN, Petersen J, Kofoed T, Crawford JS, Morsczeck C, Boysen A, Schrotz-King P.

Vaccine. 2006 Sep 29;24(40-41):6446-55. Epub 2006 Jun 12.

PMID:
16824653
20.

Susceptibility to Guillain-Barré syndrome is associated to polymorphisms of CD1 genes.

Caporale CM, Papola F, Fioroni MA, Aureli A, Giovannini A, Notturno F, Adorno D, Caporale V, Uncini A.

J Neuroimmunol. 2006 Aug;177(1-2):112-8. Epub 2006 Jul 3.

PMID:
16820217

Supplemental Content

Support Center